Cambridge Biotech Corp. (NASDAQ:CBCX) agreed to licenseDynaGen Inc.'s (NASDAQ:DYGN) technology for developingtuberculosis and other mycobacterial diagnostic products.DynaGen, of Cambridge, Mass., will supply its antigen toWorcester, Mass.-based Cambridge Biotech, which will thenproduce serology tests in the EIA microwell format as well asin rapid slide immunoassays. Cambridge Biotech will distributethe products worldwide. The market for TB testing devicescould exceed $20 million by 1994, with an annual growth ratethereafter of 9 percent.
(c) 1997 American Health Consultants. All rights reserved.